Product Description
Mechanisms of Action: V2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vantia
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Nocturia|Prostatic Hyperplasia
Phase 2: Nocturia
Phase 1: Prostatic Hyperplasia|Nocturia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
EQUINOC | P3 |
Completed |
Prostatic Hyperplasia|Nocturia |
2017-07-01 |
|
NCT02537288 | P1 |
Completed |
Nocturia |
2015-12-01 |
|
NCT02440841 | P1 |
Completed |
Nocturia |
2015-07-01 |
|
NCT01656239 | P2 |
Completed |
Nocturia |
2013-08-01 |